OncoMatch/Clinical Trials/NCT04968106
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)
Is NCT04968106 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Doxorubicin and Ifosfamide for resectable sarcoma.
Treatment: Doxorubicin · Ifosfamide · INCMGA00012 — Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Disease stage
Grade: 23
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any treatment for the disease under study
No prior treatment for the disease under study
Cannot have received: surgery, chemotherapy or radiotherapy for retroperitoneal sarcoma
Previous treatment for retroperitoneal sarcoma including surgery, chemotherapy or radiotherapy
Cannot have received: anthracyclines or anthracenediones at the maximum cumulative dose (doxorubicin, daunorubicin, epirubicin, idarubicin)
Previous treatments with doxorubicin, daunorubicin, epirubicin, idarubicin and/or other anthracyclines or anthracenediones at the maximum cumulative dose
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
left ventricular ejection fraction ≥ 50% assessed by echo or muga within 6 months from study entry
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify